Heated chemotherapy shows promise for advanced pancreatic cancer
NCT ID NCT04858009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a treatment called HIPEC, where heated chemotherapy drugs are placed directly into the abdomen during surgery. It is for people with pancreatic cancer that has spread to the lining of the abdomen. The study will enroll 40 participants to see if this approach can improve survival and control the cancer safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- heated chemotherapy (cisplatin and nab-paclitaxel) delivered directly into the abdomen
- What this could lead to
- If it works, this could offer a new treatment option to control pancreatic cancer that has spread to the abdomen, potentially extending survival.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Heated chemotherapy carries risks like infection, organ damage, and side effects from the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE PERITONEUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Home monitoring may keep cancer patients out of the ER
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New drug cocktail targets tough pancreatic tumors
- New PET tracer could light up pancreatic tumors